Novartis Korea's Sebivo to be of no NHI reimbursement.

Novartis Korea expressed a deep regret about which the NHI reimbursement for Sebivo (telvibudin), a new therapy of chronic B hepatitis infection, was not granted by the final determination of the Health Insurance Review Agency, Drug Expert Review Commission and thereby chances for many patients with B hepatitis and their new therapeutic option would be blocked.

Telvibudin was determined not ...